Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guangdong Kangmei Pharmaceutical To Set Up Subsidiary For Ginseng Business

This article was originally published in PharmAsia News

Executive Summary

Guangdong Kangmei Pharmaceutical will establish a wholly owned RMB 400 million subsidiary in Ji'an city, Jilin province to serve as a platform to complete the company's plan in the main ginseng-growing area and extend its network. With registered capital of RMB 100 million, the new set-up will mainly focus on the ginseng business, class II and III TCM, as well as local herbal planting and processing. In addition, the subsidiary plans to buy out Ji'an City Xinkaihe's assets and liabilities with less than RMB 200 million. Xinkaihe is an ginseng farming, processing, sales and R&D company. Kangmei believes the move will further optimize its resource allocation and increase revenue by RMB 120 million - 150 million in 2009. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts